Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > ingn 225

INGN 225 : Introgen Therapeutics : Vaccine

INGN 225 Cancer Vaccine Shows Promising Safety and Efficacy Results in Phase II SCLC Trial
Press release announces results of a phase II trial of INGN 225, an investigational cancer vaccine, in patients with advanced SCLC. [9/05]


Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 18-Feb-2009
Karen Parles, MLS Editor